Medicine and Dentistry
Haemophilia
100%
Albumin
74%
Immunoglobulin
68%
Blood Clotting Factor Concentrate
34%
Blood Clotting Factor 8
27%
Blood Donor
26%
Sepsis
26%
Prophylaxis
26%
Diseases
23%
Hydroxyethyl Starch
22%
Renal Replacement Therapy
22%
Blood Clotting Factor
20%
Blood Transfusion
18%
Pharmacokinetics
17%
Morbidity
16%
Alpha 1-Antitrypsin Deficiency
16%
Blood Proteins
15%
Protein Therapy
15%
Substitution Therapy
15%
Humoral Immune Deficiency
14%
Hemolysis
14%
2 Decanoylamino 3 Morpholino 1 Phenyl 1 Propanol
13%
Arm Disease
13%
Rare Disease
13%
Plasmapheresis
13%
COVID-19
13%
Prevalence
13%
Adverse Event
12%
Quality Adjusted Life Year
12%
Immune Deficiency
12%
Protein
11%
Hemophilia Therapy
11%
Bleeding Disorder
11%
Haemophilia A
10%
X Linked Agammaglobulinemia
10%
Common Variable Immunodeficiency
10%
Antibody
9%
Decision Making
9%
Transfusion
9%
Blood Safety
9%
Threat
9%
Meta-Analysis
9%
Sensitivity Analysis
8%
Wellbeing
8%
Self Report
8%
Bleeding
8%
Essential Medicines
6%
Neutralizing Antibody
6%
Biological Activity
6%
Fluid Resuscitation
6%
Social Sciences
Therapy
60%
Cost Effectiveness
28%
Health Economics
22%
Prophylaxis
18%
Donation
18%
Decision Making
15%
Regulatory Agency
13%
Arms Control
13%
Federation
13%
Expenditure
13%
Shortage
13%
Statistical Dispersion
13%
Morbidity
10%
Self-Sufficiency
9%
Proteins
9%
Effectiveness
8%
Quality of Life
5%
Pharmacology, Toxicology and Pharmaceutical Science
Albumin
52%
Hemophilia
29%
Immunoglobulin
27%
Sepsis
15%
2 Decanoylamino 3 Morpholino 1 Phenyl 1 Propanol
13%
Arm Disease
13%
Hetastarch
13%
Adverse Event
12%
Blood Clotting Factor Concentrate
11%
Humoral Immune Deficiency
10%
Clinical Trial Design
9%
Morbidity
8%
Phase IV
6%
Bleeding Disorder
6%
Antibody
6%
Prevalence
6%
Thrombosis
6%
Blood Clotting Factor
6%
Hemolysis
5%
Ethanol
5%
Thromboembolism
5%
Liver Cirrhosis
5%